Carna Health Named to Fortune’s 2026 List of America’s Most Innovative Companies
Carna Health, a pioneering digital health company focused on transforming kidney care and addressing cardio-kidney metabolic (CKM) conditions, has earned a place on Fortune’s prestigious list of America’s Most Innovative Companies for 2026. This recognition highlights the company’s commitment to advancing healthcare through cutting-edge technology, data-driven insights, and a patient-centered approach. The award, presented by Fortune in collaboration with Statista Inc., a globally recognized statistics and industry ranking provider, was officially announced on March 25, 2026, and is currently featured on Fortune’s website.
The America’s Most Innovative Companies ranking is widely regarded as one of the most comprehensive assessments of corporate innovation in the United States. It evaluates organizations based on three key pillars: product innovation, process innovation, and innovation culture. These dimensions collectively provide a holistic view of how companies create value, adapt to change, and foster forward-thinking environments.
To assess innovation culture and internal perceptions of process innovation, Statista conducted extensive online surveys among employees across a wide range of companies. These surveys allowed employees to provide candid feedback on their organizations’ creativity, openness to new ideas, and commitment to continuous improvement. By incorporating internal perspectives, the ranking captures how innovation is experienced within the company, not just how it is presented externally.
In addition to internal feedback, Statista gathered external insights on product and process innovation through surveys of industry experts. These experts included recruiters, management consultants, and patent attorneys—professionals with deep knowledge of market trends, organizational effectiveness, and technological advancements. Their evaluations added an important layer of objectivity and industry-wide perspective to the ranking process.
Another crucial component of the evaluation involved analyzing companies’ intellectual property portfolios. For this purpose, Statista partnered with LexisNexis® Intellectual Property Solutions, leveraging its advanced platform to assess both the quantity and quality of patents held by each organization. This analysis provided a data-driven measure of innovation output, reflecting how effectively companies are translating ideas into tangible, protected assets.
Out of a vast pool of eligible organizations, only the top 300 U.S. companies with the highest overall scores were selected for inclusion in the final ranking. Carna Health not only secured a place on this exclusive list but also distinguished itself by ranking among the top 100 companies overall. This achievement places the company in the top 1% of all evaluated organizations, underscoring its exceptional performance across multiple dimensions of innovation.
Carna Health’s particularly strong scores in process innovation and innovation culture highlight its ability to optimize operations while fostering an environment that encourages creativity and collaboration. These strengths are especially important in the healthcare sector, where innovation must be both rapid and reliable to effectively improve patient outcomes.
At the heart of Carna Health’s success is its mission to revolutionize the management and treatment of cardio-kidney metabolic syndrome—a complex and increasingly prevalent set of conditions that includes chronic kidney disease, cardiovascular disease, and metabolic disorders such as diabetes. By leveraging artificial intelligence and vast global datasets, the company aims to predict disease progression more accurately and enable earlier, more targeted interventions.
Dr. Salvatore Viscomi, CEO and Co-Founder of Carna Health, emphasized the significance of the recognition, noting that it reflects the dedication and ingenuity of the company’s team. He highlighted that innovation is deeply embedded in the organization’s mission, driving efforts to develop advanced tools that empower clinicians and improve patient care. According to Dr. Viscomi, the company’s approach combines predictive analytics with practical clinical applications, ensuring that technological advancements translate into real-world benefits.
One of Carna Health’s key innovations lies in its use of AI-driven models to analyze patient data and identify patterns that may indicate increased risk of disease progression. These models integrate information from diverse populations around the world, enabling more accurate predictions across different demographic groups. By providing clinicians with actionable insights, the company helps facilitate earlier diagnosis, more personalized treatment plans, and better overall management of CKM conditions.
Equally important is Carna Health’s focus on equipping local healthcare providers with the tools and knowledge they need to deliver effective care. Rather than replacing clinicians, the company’s technology is designed to augment their capabilities, enhancing decision-making and improving efficiency. This collaborative approach ensures that innovation is not only technologically advanced but also practical and accessible.
The recognition from Fortune and Statista serves as validation of Carna Health’s efforts to push the boundaries of digital health. It also highlights the growing importance of innovation in addressing some of the most pressing challenges in healthcare today. As chronic diseases continue to rise globally, the need for scalable, data-driven solutions has never been greater.
Statista’s role in the ranking process further reinforces the credibility of the award. As a leading provider of data and market intelligence, Statista publishes hundreds of industry rankings and company analyses in partnership with prominent media organizations. Its rigorous methodology and reliance on both qualitative and quantitative data ensure that its rankings are both comprehensive and reliable.
The collaboration between Statista and Fortune brings together analytical expertise and editorial authority, resulting in a ranking that is widely respected across industries. For companies like Carna Health, inclusion on this list not only enhances visibility but also signals to investors, partners, and customers that the organization is at the forefront of innovation.
Looking ahead, Carna Health is well-positioned to build on this recognition and continue its trajectory of growth and impact. The company’s commitment to innovation, combined with its focus on improving patient outcomes, suggests that it will remain a key player in the evolving landscape of digital healthcare.
In conclusion, Carna Health’s inclusion in Fortune’s 2026 list of America’s Most Innovative Companies represents a significant milestone for the organization. It reflects the company’s ability to integrate advanced technology, data analytics, and a strong innovation culture to address complex healthcare challenges. As the industry continues to evolve, Carna Health’s achievements serve as an example of how innovation can drive meaningful change and improve lives on a global scale.
About Carna Health
Carna Health is a global, AI-enabled digital health company transforming Cardio-Kidney-Metabolic (CKM) care. Founded in 2021, the company addresses the silent progression of chronic kidney disease (CKD) and related metabolic conditions through early detection and coordinated care. Its intelligent platform combines point-of-care and laboratory diagnostics with AI-driven analytics to enable population-scale screening and continuous monitoring. By aggregating clinical data into a secure Patient 360 view, Carna Health identifies undiagnosed risk, predicts disease progression, and delivers actionable insights to providers and patients, particularly in settings with limited specialist access
